SCHEMBL15329220

SCHEMBL15329220

COc1cc(OC)c2c(=O)[nH]ccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 2/20 0.50
PDE3A Q14432 2/20 0.50
ABCG2 Q9UNQ0 2/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
POLB P06746 1/20 0.42
MAPK1 P28482 1/20 0.42
EGFR P00533 2/20 0.41
CHEK1 O14757 3/20 0.40
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
GAA P10253 2/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
MAOA P21397 1/20 0.39
ABCB1 P08183 1/20 0.39
XDH P47989 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21593366 0.82 CHEK1 (0.48) CHEK1
SCHEMBL1748919 0.77 MEN1 (0.48) PDE3BPDE3AMEN1KMT2APOLB
SCHEMBL14671417 0.75 HSD17B10 (0.45) PDE3BPDE3AABCG2KMT2AALDH1A1
SCHEMBL4500573 0.73 ABCG2 (0.49) PDE3BPDE3AABCG2MEN1KMT2A
SCHEMBL18643548 0.73 PDE3B (0.62) PDE3BPDE3AABCG2MEN1KMT2A
SCHEMBL24136649 0.73 MAPT (0.41) MEN1KMT2APOLBMAPK1CHEK1
SCHEMBL374997 0.72 ROCK1 (0.56) MEN1KMT2APOLBMAPK1ALDH1A1
SCHEMBL30386054 0.71 ALDH1A1 (0.58) PDE3BPDE3AABCG2POLBMAPK1
SCHEMBL29039486 0.71 ALDH1A1 (0.58) PDE3BPDE3AABCG2POLBMAPK1
SCHEMBL311502 0.71 PDE3B (0.48) PDE3BPDE3AABCG2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107252429-B Novel anti-inflammatory agent 雷斯韦洛吉克斯公司 2023-06-16 CN disclosed
US-20160346291-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION RESVERLOGIX CORP (CA) 2016-12-01 US disclosed
EP-3035933-A2 COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION Resverlogix Corporation (CA) 2016-06-29 EP disclosed
WO-2015025228-A2 COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION RESVERLOGIX CORP. (CA) 2015-02-26 WO disclosed
US-20130281397-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281397-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION BRD4, BMI1, BRPF3 PDE3B 4743/4885PDE3A 4734/4885ABCG2 4840/4885
US-20160346291-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION PCSK9, TGFB1, HMGCR PDE3B 109/4885PDE3A 123/4885ABCG2 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.